We appreciate the comments from Dr Batalla and coworkers from Spain, who also observed a very high prevalence of elevated LDL cholesterol (>2.59 mmol/L [>100 mg/dL]) that persisted for more than 2 years following hospitalization for coronary heart disease.
On behalf of the GIFA study, Dr Sgadari points out the extreme paucity of lipid-lowering therapy (3%) in the cohort with coronary heart disease and elevated mean total cholesterol. Whether the lower rate of lipid-lowering therapy use in women is attributable to age-related differences between the sexes is an interesting question that unfortunately cannot be resolved in the Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial1 owing to the relatively small number of participating women and associated lack of statistical power to formally test this hypothesis.
Miller M, Byington R. Toward Better Therapy of Hypercholesterolemia—Reply. Arch Intern Med. 2000;160(17):2685-2686. doi: